Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System.

March
SunMonTueWedThuFriSat
2324252627281234567891011121314151617181920212223242526272829303112345
March
SunMonTueWedThuFriSat
2324252627281234567891011121314151617181920212223242526272829303112345
Copyright © Ark Medical Solutions Inc. All Rights Reserved.